The role of chemoradiotherapy in the treatment of stage III non-small-cell lung cancer

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Eberhardt, W ^a   Gauler, T ^a   Hepp, R ^b   Korfee, S ^a   Pottgen C ^a   Stamatis, G ^c   Stuschke, M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HOSPITAL PADRE HURTADO   (Chile)

^c RUHRLANDKLINIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; UFT; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; ELDERLY CARE; EVIDENCE BASED MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAINTENANCE THERAPY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RESPIRATORY DISTRESS SYNDROME; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKULL IRRADIATION; TEAMWORK; TREATMENT OUTCOME; TREATMENT PLANNING;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LUNG NEOPLASMS;

EID: 9744273910     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh907     Document Type: Article

References (62)

1. Levi F, Lucchini F, Negri E et al. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer 2004; 110: 155-169.
2. Jemal A, Tiwari R, Murray T et al. Cancer statistics. CA Cancer J Clin 2004; 54: 8-29.
3. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In DeVita VT Jr, Hellman S, Rosenberg SA (edt): Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia, PA: Lippincott 1997; 858-911.
4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
5. Albain KS, Pass HI. Induction therapy for locally advanced non-small-cell lung cancer. In Pass HJ, Mitchell J, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia, PA: Lippincott 2000; 798-820.
6. Ginsberg RJ. Multimodality treatment of resectable non small-cell lung cancer. Clin Lung Cancer 2000; 1: 194-200; discussion 201.
7. Johnson DH, Turrisi AT, Pass HJ. Combined modality treatment for locally advanced non-small cell lung cancer. In Pass HJ, Mitchell J, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia, PA: Lippincott 1996; 863-873.
8. Eberhardt WE, Albain KS, Pass H et al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 2003; 42 (Suppl 1): S9-14.
9. Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non small cell lung cancer (NSCLC): heterogeneity of prognosis and evidences for a subclassification. J Clin Oncol 2000; 18: 2981-2989.
10. Grunenwald D, LeChevalier T. Stage category of non-small cell lung cancer: A new proposal. J Natl Cancer Inst 1997; 89: 88-89.
11. Eberhardt W, Bildat S, Korfee S. Combined modality therapy in NSCLC. Ann Oncol 2000; 11 (Suppl 3): 85-95.
12. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95: 1453-1461.
13. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
14. Winton TL, Livingston R, Johnson D et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Proc Am Soc Clin Oncol 2004; 23: (Abstr 7018).
15. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol 2004; 23: (Abstr 7019).
16. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000; 343: 1217-1222.
17. Zatloukal P, Petruzelkab L, Zemanovab M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; In press.
18. Pierre F, Maurice P, Gilles R et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC) (GLOTGFPC NPC 95-01 study). Proc Ant Soc Clin Oncol 2001; 20: (Abstr 1246).
19. Curran W, Scott C, Langer C et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22: 621 (Abstr 2499).
20. Huber R, Flentje H, Gosse B et al. Induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB): update of CT/RT 99/97. Proc Am Soc Clin Oncol 2004; 23: 632 (Abstr 7075).
21. Albain K, Scott CB, Rush VR et al. Phase-II study of concurrent chemotherapy and full course radiotherapy versus CT/RT induction followed by surgical resection for stage IIIA(N2) non-small-cell lung cancer: First outcome analysis of North American Intergroup trial 0139. Proc Am Soc Clin Oncol 2003; 21: 621 (Abstr 2497).
22. Albain KS, Crowley JJ, Turrisi AT 3rd et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-3460.
23. Gandara DR, Chansky K, Albain K et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21: 2004-2010.
24. Vokes EE, Herndon JE, Crawford J et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002; 20: 4191-4198.
25. Vokes EE, Herndon JE, Kelley MJ et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer: Initial analysis of a randomized phase-III trial. Proc Am Soc Clin Oncol 2004; 23: 616 (Abstr 7005).
26. Ball D, Bishop J, Smith J et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999; 52: 129-136.
27. Sibley GS, Mundt AJ, Shapiro C et al. The treatment of stage III non small cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys 1995; 33: 1001-1007.
28. Hayman JA, Martel MK, Ten Haken RK et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001; 19: 127-136.
29. Rosenzweig KE, Yorke E, Jackson A et al. Results of a phase I dose escalation study in the treatment of inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 57: S417-S418.
30. Bradley JD, Ieumwananonthachai N, Purdy JA et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52: 49-57.
31. Chen LM, Ignacio L, Jacobs R et al. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer. Radiat Oncol Investig 1999; 7: 49-53.
32. Socinski MA, Rosemnan JG, Halle J et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001; 92: 1213-1223.
33. Maguire PD, Marks LB, Sibley GS et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol 2001; 19: 705-711.
34. Belani P, Wang W, Johnson DH et al. Induction chemotherapy followed by standard thoracic radiotherapy (Std.TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage III A & B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 2003; 22: 622 (Abstr 2500).
35. Lehmann D, Leetz HK, Hodapp N et al. Physical and technical quality assurance in the CHARTWEL-Bronchus trial. Strahlenther Onkol 2003; 179: 152-157.
36. Saunders M, Dische S, Barrett A et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee. Radiother Oncol 1999; 52: 137-148.
37. Timmerman R, Papiez L, McGarry R et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124: 1946-1955.
38. Viney RC, Boyer MJ, King MT et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004; 22: 2357-2362.
39. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2527.
40. Hoekstra CJ, Stroobants SG, Hoekstra OS et al. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003; 39: 151-157.
41. Hoekstra CJ, Hoekstra OS, Stroobants SG et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002; 43: 1304-1309.
42. Bradley J, Thorstad WL, Mutic S et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59: 78-86.
43. Albain K, Scott CB, Rush VR et al. Phase-II study of concurrent chemotherapy and full course radiotherapy versus CT/RT induction followed by surgical resection for stage IIIA(N2) non-small-cell lung cancer: First outcome analysis of North American Intergroup trial 0139. Lung Cancer 2003; 41: S4 (Abstr PL-4).
44. Eberhardt W, Korfee S, Pöttgen C et al. Operable stage IIIA NSCLC: Prospectively randomized multicenter German trial of surgery and postoperative radiotherapy versus "trimodality treatment" - Analysis of surgical results and toxicity. J Cancer Res Clin Oncol 2004; 130 (Suppl 1):S72.
45. Thomas M, Macha HN, Ukena D et al. Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG). Proc Am Soc Clin Oncol 2004; 23: 616 (Abstr 7004).
46. Grunenwald DH, Andre F, Le Pechoux C et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or T3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001; 122: 796-802.
47. Ichinose Y, Fukuyama Y, Asoh H et al. Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer. Ann Thorac Sing 2003; 76: 1810-1814.
48. Machtay M, Lee JH, Stevenson JP et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long term results and associations with pathologic response. J Thorac Cardiovasc Surg 2004; 127: 108-113.
49. DeCamp MM, Rice TW, Adelstein DJ et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Sung 2003; 126: 17-27.
50. Katayama H, Ueoka H, Kiura K et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 2004; 90: 979-984.
51. Ahn YC, Park K, Kim DY et al. Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer. Acta Oncol 2001; 40: 588-592.
52. Gauler T, Eberhardt W, Le Pechoux W et al. Multicenter German/French phase II trial of induction CTX followed by concurrent CTX/RTX plus/minus surgery in locally far advanced inoperable non-small-cell lung cancer stages III (N2) and IIIB - Mature results of a novel induction CTX regimen. J Cancer Res Clin Oncol 2004; 130 (Suppl 1): S72.
53. Trodella L, Granone P, Valente S et al. Neoadjuvant concurrent radio-chemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 2004; 15: 389-398.
54. Freidel G, Budach W, Spengler W et al. Phase II trial on neo-adjuvant chemoradiation with paclitaxel/carboplafin in stage III NSCLC. J Cancer Res Clin Oncol 2004; 130 (Suppl 1): S72.
55. Martin J, Ginsberg R, Abolhoda A et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001; 72: 1149-1154.
56. Stamatis G, Djuric D, Eberhardt WE et al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer; an analysis of 350 operated patients. Eur J Cardiothorac Surg 2002; 22: 292-297.
57. Rusch VW, Giroux DJ, Kraut MJ et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup trial 0160). J Thorac Cardiovasc Surg 2001; 121: 472-483.
58. Tsuboi M, Kunitoh H, Kato H et al. A phase II trial of pre-operative chemoradiotherapy followed by surgery in Pancoast tumours: initial report of Japan Clinical Oncology Group trial (JCOG 9896). Lung Cancer 2003; 41: A78.
59. Schild SE, Stella PJ, Geyer SM et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21: 3201-3206.
60. Socinski MA, Zhang C, Herndon JE et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004; 15: 1033-1041.
61. Stuschke M, Eberhardt W, Pöttgen C et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multi-modality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999; 17: 2700-2709.
62. Robnett TJ, Machtay M, Stevenson JP et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 2001; 19: 1344-1349.